Dr Kurosh Hakimizadeh Reihani, DDS | |
240 S Lacienega Blvd, #401, Bh, CA 90211 | |
(310) 657-0777 | |
Not Available |
Full Name | Dr Kurosh Hakimizadeh Reihani |
---|---|
Gender | Male |
Speciality | Dentist |
Location | 240 S Lacienega Blvd, Bh, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316097546 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
122300000X | Dentist | 36420 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Kurosh Hakimizadeh Reihani, DDS 240 S Lacienega Blvd, #401, Bh, CA 90211 Ph: (310) 657-0777 | Dr Kurosh Hakimizadeh Reihani, DDS 240 S Lacienega Blvd, #401, Bh, CA 90211 Ph: (310) 657-0777 |
News Archive
Fatigue, weight gain, chills, hair loss, anxiety, excessive perspiration - these symptoms are a few of the signs that the thyroid gland, which regulates the body's heart rate and plays a crucial role in its metabolism, has gone haywire.
A novel therapy recently approved by the U.S. Food and Drug Administration for patients with Alzheimer's disease amid considerable controversy should not be prescribed by physicians off-label for cerebral amyloid angiopathy (CAA), a similar cerebrovascular condition, according to Steven Greenberg, MD, PhD, director of the Hemorrhagic Stroke Research Program at Massachusetts General Hospital (MGH) and president of the International Cerebral Amyloid Angiopathy Association (ICAAA).
ytRx Corporation, a biopharmaceutical company, today announced favorable preliminary results from its Phase 2 STAR-1 registration clinical trial for tamibarotene in the treatment of acute promyelocytic leukemia (APL) in patients failing other treatments.
Medical errors are estimated to cause 250,000 deaths per year in the US. Previously, research on admitted patients suggested that errors are due to the way doctors process the data they have about patients - in other words, doctors have the right information, but might not act on it in the best way.
› Verified 7 days ago